• Vaccine Name: Brucella suis delta mapB outer membrane vesicle subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009570
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Pig
• Host Species as Laboratory Animal Model: Mus musculus
• Antigen: MapB deletion; outer membrane vesicles
• Preparation: OMVs were isolated from B. suis ΔmapB mutant strain using ultracentrifugation and characterized by electron microscopy, dynamic light scattering, SDS-PAGE, and proteomics; no adjuvant was reported. (González et al, 2024)
• Description: Brucella suis ΔmapB outer membrane vesicles (OMVs) were characterized and evaluated as an acellular vaccine candidate to protect against systemic and mucosal B. suis infection, addressing the lack of available vaccines for swine brucellosis. Efficacy: Immunization with ΔmapB OMVs induced higher antigen-specific IgG titers than wild-type OMVs; antibodies reduced bacterial adherence and invasion and enhanced phagocytosis; ΔmapB OMVs induced stronger Th1 cellular responses; both OMVs conferred protection against intratracheal challenge, but ΔmapB OMVs provided superior protection against intraperitoneal infection. Immune response: ΔmapB OMVs elicited robust humoral immunity with high IgG titers and functional antibodies; cellular immunity was characterized by elevated secretion of interleukin-17 and gamma interferon, indicating a strong T helper 1 response. (González et al, 2024)

Mouse Response

• Immune Response: ΔmapB OMVs elicited robust humoral immunity with high IgG titers and functional antibodies; cellular immunity was characterized by elevated secretion of interleukin-17 and gamma interferon, indicating a strong T helper 1 response. (González et al, 2024)
• Challenge Protocol: Mice were intramuscularly immunized with ΔmapB OMVs or wild-type OMVs; antigen-specific antibody levels and functional assays (inhibition of bacterial adherence/invasion, enhancement of phagocytosis) were performed; cellular immunity was assessed by cytokine secretion (IL-17, IFN-gamma) after spleen cell stimulation; protection was evaluated by challenging mice intraperitoneally or intratracheally with virulent B. suis and quantifying bacterial … [truncated; see source audit]. (González et al, 2024)
• Efficacy: Immunization with ΔmapB OMVs induced higher antigen-specific IgG titers than wild-type OMVs; antibodies reduced bacterial adherence and invasion and enhanced phagocytosis; ΔmapB OMVs induced stronger Th1 cellular responses; both OMVs conferred protection against intratracheal challenge, but ΔmapB OMVs provided superior protection against intraperitoneal infection. (González et al, 2024)
• Description: Mice were intramuscularly immunized with ΔmapB OMVs or wild-type OMVs; antigen-specific antibody levels and functional assays (inhibition of bacterial adherence/invasion, enhancement of phagocytosis) were performed; cellular immunity was assessed by cytokine secretion (IL-17, IFN-gamma) after spleen cell stimulation; protection was evaluated by challenging mice intraperitoneally or intratracheally with virulent B. suis and quantifying bacterial load. (González et al, 2024)